TITLE

Failure of a prospective trial to detect cytomegalovirus retinitis after initiation of highly

AUTHOR(S)
Uphold, Constance R.; Smith, Fran
PUB. DATE
December 1998
SOURCE
AIDS Patient Care & STDs;Dec98, Vol. 12 Issue 12, p907
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Determines the incidence of cytomegalovirus (CMV) retinis prior to and after initiation with highly active antiretroviral therapy (HAART). Decrease in viral loads and increase in CD4+ T-cell counts after starting HAART; Non-occurrence of CMV retinis among patients receiving HAART; Development of CMV retinis after HAART.
ACCESSION #
1487484

 

Related Articles

  • Discontinuation of Secondary Prophylaxis in Patients with Cytomegalovirus Retinitis Who Have Responded to Highly Active Antiretroviral Therapy. Berenguer, Juan; Gonz á lez, Juan; Pulido, Federico; Padilla, Bel é n; Casado, Jos é Luis; Rubio, Rafael; Arribas, Jos é Rarm ó n // Clinical Infectious Diseases;2/1/2002, Vol. 34 Issue 3, p394 

    We performed a prospective study of discontinuation of sec-ondary prophylaxis against cytomegalovirus (CMV) in 36 patients with acquired immunodeficiency syndrome and qui-escent CMV retinitis after successful treatment with highly active antiretroviral therapy (HAART). No reactivation or ...

  • HAART PREVENTS CVM PROGRESSION.  // AIDS Patient Care & STDs;Feb2000, Vol. 14 Issue 2, p101 

    Discloses research findings that patients taking highly active antiretroviral therapy (HAART) regimens may be able to stop taking their anti-CMV medications without progression of retinitis. Ability of HAART to rejuvenate the immune system sufficiently enough to control CMV retinitis without...

  • Treat HIv-1 Infected with at Least Two Antiretrovirals.  // Kidney;Sep/Oct99, Vol. 8 Issue 5, p203 

    Discusses an abstract of the article, entitled `Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients,' by T.S. Ahuja, N. Niaz. A. Velasco and others.

  • VIRACEPT COMBINATIONS STUDIES.  // AIDS Patient Care & STDs;Jun98, Vol. 12 Issue 6, p495 

    Presents information on the fifth Conference on Retroviruses and Opportunistic Infections in Chicago in 1998. Summarization of the results from clinical trials of the drug Viracept; Use of the drug with other protease inhibitors and anti-human immunodeficiency virus (HIV) drugs; Evaluation of...

  • Stavudine Once Daily. Cheer, S.M.; Goa, K.L. // Drugs;2002, Vol. 62 Issue 18, p2667 

    â–´ Stavudine administered once daily is a nucleoside analogue reverse transcriptase inhibitor. â–´ The efficacy (reduction in viral load and increase in CD4+ lymphocyte counts from baseline) of stavudine once daily-containing triple therapy was similar to that of stavudine immediate...

  • Abacavir Hypersensitivity Reaction. Hewitt, Ross G. // Clinical Infectious Diseases;4/15/2002, Vol. 34 Issue 8, p1137 

    A hypersensitivity reaction occurs in association with initiation of abacavir therapy as part of combination antiretroviral therapy in ∼3.7% of patients. The reaction is possibly the result of a combination of altered drug metabolism and immune dysfunction, which is poorly understood....

  • A Cohort Study of Nevirapine Tolerance in Clinical Practice: French Aquitaine Cohort, 1997--1999. Bonnet, F.; Lawson-Ayayi, S.; Thiébaut, R.; Ramanampamonjy, R.; Lacoste, D.; Bernard, N.; Malvy, D.; Bonarek, M.; Djossou, F.; Beylot, J.; Dabis, F.; Morlat, P. // Clinical Infectious Diseases;11/15/2002, Vol. 35 Issue 10, p1231 

    We performed a retrospective study to evaluate, under routine circumstances, the tolerance and immunovirological changes associated with antiretroviral regimens that contain nevirapine in 137 patients (88% were antiretroviral experienced). During a mean follow-up of 11 months, 33% of patients...

  • Approaching Eradication of Highly Active Antiretroviral Therapy-Persistent Human Immunodeficiency Virus Type 1 Reservoirs with Immune Activation Therapy. Kulkosky, Joseph; Pomerantz, Roger J. // Clinical Infectious Diseases;12/15/2002, Vol. 35 Issue 12, p1520 

    Highly active antiretroviral therapy (HAART) has dramatically altered the human immunodeficiency virus type 1 (HIV-1) pandemic in the developed world. Most patients treated with HAART will maintain clinically undetectable plasma virus loads with concomitant dramatic decreases in mortality and...

  • Immune Reconstitution Cryptococcosis after Initiation of Successful Highly Active Antiretroviral Therapy. Jenny-Avital, Elizabeth R.; Abadi, Maria // Clinical Infectious Diseases;12/15/2002, Vol. 35 Issue 12, p128 

    Five of 10 patients who commenced successful highly active antiretroviral therapy (HAART) for infection with human immunodeficiency virus type 1 (HIV-1) concurrent with or soon after a diagnosis of cryptococcal infection experienced clinical events characterized by sterile inflammation. Two...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics